Ulcerative pyoderma gangrenosum is a rare inflammatory disease with an incidence of 3–10 cases per million per year. 1 Consideration of the diagnosis is based on its classic morphological features: ...

Pyoderma gangrenosum is an ulcerating disorder of the skin with sterile neutrophilic inflammation that may be seen in up to 5% of patients with chronic ulceration of the legs. 1 Typically painful, it ...

JENA, Germany, March 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement ...

Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMAProductive end-of-phase II meeting with FDA held for PG; dialogue ongoing related to Phase III program ...

Phase 3 pyoderma gangrenosum trial was halted after analysis of 30 patients showed no efficacy signal. InflaRx to prioritize INF904 with key data expected in chronic spontaneous urticaria and ...